Lipoxygenase inhibitors as potential cancer chemopreventives

Cancer Epidemiology Biomarkers and Prevention

Volumn 8, Issue 5, 1999, Pages 467-483

  Steele, Vernon E ^a   Holmes, Cathy A ^b   Hawk, Ernest T ^a   Kopelovich, Levy ^a   Lubet, Ronald A ^a   Crowell, James A ^a   Sigman, Caroline C ^b   Kelloff, Gary J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b CCS Associates   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 ETHYL 6 [[3 FLUORO 5 (3,4,5,6 TETRAHYDRO 4 METHOXY 2H PYRAN 4 YL)]PHENOXYMETHYL] 1 METHYL 2 QUINOLONE; 2 [2 PROPYL 3 [3 [2 ETHYL 4 (4 FLUOROPHENYL) 5 HYDROXYPHENOXY]PROPOXY]PHENOXY]BENZOIC ACID; 2 CYCLOPENTYL 2 [4 (2 QUINOLINYLMETHOXY)PHENYL]ACETIC ACID; 3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 (2 QUINOLINYLMETHOXY) 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; 3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; 4 (4 CARBOXYPHENYLTHIO) 7 [4 (4 PHENOXYBUTOXY)PHENYL] 5 HEPTENOIC ACID; 5 [2 (2 CARBOXYETHYL) 3 [6 (4 METHOXYPHENYL) 5 HEXENYLOXY]PHENOXY]VALERIC ACID; 6 [[3 FLUORO 5 (3,4,5,6 TETRAHYDRO 4 METHOXY 2H PYRAN 4 YL)]PHENOXYMETHYL] 1 METHYL 2 QUINOLONE; 7 [3 (4 ACETYL 3 METHOXY 2 PROPYLPHENOXY)PROPOXY] 3,4 DIHYDRO 8 PROPYL 2H 1 BENZOPYRAN 2 CARBOXYLIC ACID; 7 [3 [2 (CYCLOPROPYLMETHYL) 3 METHOXY 4 (4 THIAZOLYL)PHENOXY]PROPOXY] 3,4 DIHYDRO 8 PROPYL 2H 1 BENZOPYRAN 2 CARBOXYLIC ACID; 7 [3 [2 CYCLOPROPYLMETHYL 3 METHOXY 4 [(METHYLAMINO)CARBONYL]PHENOXY]PROPOXY] 3,4 DIHYDRO 8 PROPYL 2H 1 BENZOPYRAN 2 PROPANOIC ACID; ALPHA METHYL 6 (2 QUINOLYLMETHOXY) 2 NAPHTHYLACETIC ACID; ANTINEOPLASTIC AGENT; ARACHIDONATE 5 LIPOXYGENASE; BAICALEIN; DOCEBENONE; ESCULETIN; IRALUKAST; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LIPOXYGENASE; LIPOXYGENASE INHIBITOR; MONTELUKAST; MOXILUBANT MALEATE; PRANLUKAST; QUINOLINE DERIVATIVE; UNCLASSIFIED DRUG; ZAFIRLUKAST; ZILEUTON;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER CHEMOTHERAPY; DRUG EFFECT; DRUG MECHANISM; DRUG STRUCTURE; ENZYME INHIBITION; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH;

ANIMALS; ANTICARCINOGENIC AGENTS; HUMANS; LIPOXYGENASE INHIBITORS; NEOPLASMS; RATS;

EID: 0032894886     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (244)

1. Honn, K. V., Tang, D. G., Gao, X., Butovich, I. A., Liu, B., Timar, J., and Hagmann, W. 12-Lipoxygenases and 12(S)-HETE: role in cancer metastasis. Cancer Metastasis Rev., 13: 365-396, 1994.
2. Chen, Y. Q., Duniec, Z. M., Liu, B., Hagmann, W., Gao, X., Shimoji, K., Marnett, L. J., Johnson, C. R., and Honn, K. V. Endogenous 12(S)-HETE production by tumor cells and its role in metastasis. Cancer Res., 54: 1574-1579, 1994.
3. Gao, X., Grignon, D. J., Chbihi, T., Zacharek, A., Chen, Y. Q., Sakr, W., Porter, A. T., Crissman, J. D., Pontes, J. E., Powell, I. J., and Honn, K. V. Elevated 12-lipoxygenase mRNA expression correlates with advanced stage and poor differentiation of human prostate cancer. Urology, 46: 227-237, 1995.
4. Tang, D. G., and Honn, K. V. 12-Lipoxygenase, 12(S)-HETE, and cancer metastasis. Ann. NY Acad. Sci., 744: 199-215, 1994.
5. Timar, J., Raso, E., Fazakas, Z. S., Silletti, S., Raz, A., and Honn, K. V. Multiple use of a signal transduction pathway in tumor cell invasion. Anticancer Res., 16: 3299-3306, 1996.
6. Liu, B., Maher, R. J., Hannun, Y. A., Porter, A. T., and Honn, K. V. 12(S)-HETE enhancement of prostate tumor cell invasion: selective role of PKCα. J. Natl. Cancer Inst., 86: 1145-1151, 1994.
7. Liu, B., Timar, J., Howlett, J., Diglio, C. A., and Honn, K. V. Lipoxygenase metabolites of arachidonic and linoleic acids modulate the adhesion of tumor cells to endothelium via regulation of protein kinase C. Cell Regul., 2: 1045-1055, 1991.
8. Liu, Y-W., Chen, B-K., Chen, C-J., Arakawa, T., Yoshimoto, T., Yamamoto, S., and Chang, W-C. Epidermal growth factor enhances transcription of human arachidonate 12-lipoxygenase in A431 cells. Biochim. Biophys. Acta. 1344: 38-46, 1997.
9. Dethlefsen, S. M., Shepro, D., and D'Amore, P. A. Arachidonic acid metabolites in bFGF-, PDGF-, and serum-stimulated vascular cell growth. Exp. Cell. Res., 212: 262-273, 1994.
10. Schade, U. F., Ernst, M., Reinke, M., and Wolter, D. T. Lipoxygenase inhibitors suppress formation of tumor necrosis factor in vitro and in vivo. Biochem. Biophys. Res. Commun., 159: 748-754, 1989.
11. Stenke, L., Mansour, M., Reizenstein, P., and Lindgren, J. A. Stimulation of human myelopoiesis by leukotrienes B4 and C4: interactions with granulocyte-macrophage colony-stimulating factor. Blood, 81: 352-356, 1993.
12. Denzlinger, C., Walther, J., Wilnranns, W., and Gerhartz, H. H. Interleukin-3 enhances the endogenous leukotricne production. Blood, 81: 2466-2468, 1993.
13. Honn, K. V., Timar, J., Rozhin, J., Bazaz, R., Sameni, M., Ziegler, G., and Sloane, B. F. A lipoxygenase metabolite, 12-(S)-HETE, stimulates protein kinase C-mediated release of eathepsin B from malignant cells. Exp. Cell Res., 214: 120-130, 1994.
14. Tang, D. G., Grossi, I. M., Chen, Y. Q., Diglio, C. A., and Honn, K. V. 12(S)-HETE promotes tumor-cell adhesion by increasing surface expression of αVβ3 integrins on endothelial cells. Int. J. Cancer, 54: 102-111, 1993.
15. Chopra, H., Timar, J., Chen, Y. Q., Rong, X., Grossi, I. M., Fitzgerald, L. A., Taylor, J. D., and Honn, K. V. The lipoxygenase metabolite 12(S)-HETE induces a cytoskeleton-dependent increase in surface expression of integrin αIIbβ3 on melanoma cells. Int. J. Cancer, 49: 774-786, 1991.
16. Ghosh, J., and Myers, C. E. Arachidonic acid stimulates prostate cancer cell growth: critical role of 5-lipoxygenase. Biochem. Biophys. Res. Commun., 235: 418-423, 1997.
17. Samuelsson, B., Dahlen, S-E., Lindgren, J. A., Rouzer, C. A., and Serhan, C. N. Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science (Washington DC), 237: 1171-1176, 1987.
18. Needleman, P., Turk, J., Jaksehik, B. A., Morrison, A. R., and Lefkowith, J. B. Arachidonic acid metabolism. Annu. Rev. Biochem., 55: 69-102, 1986.
19. Lewis, R. A., Austen, K. F., and Soberman, R. J. Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases. N. Engl. J. Med., 323: 645-655, 1990.
20. Clark, M. A., Ozgur, L. E., Conway, T. M., Dispoto, J., Crooke, S. T., and Bomalaski, J. S. Cloning of a phospholipase A2-activating protein. Proc. Natl. Acad. Sci. USA, 88: 5418-5422, 1991.
21. Piper, P. J. Leukotrienes. Potent mediators of airway constriction. Int. Arch. Allergy Immunol., 76: 43-48, 1985.
22. Coleman, R. A., Eglen, R. M., Jones, R. L., Narumiya, S., Shimizu, T., Smith, W. L., Dahlen, S-E., Drazen, J. M., Gardiner, P. J., Jackson, W. T., Jones, T. R., Krell, R. D., and Nicosia, S. Prostanoid and leukotriene receptors: a progress report from the IUPHAR working parties on classification and nomenclature. Adv. Prostaglandin Thromboxane Leukotriene Res., 23: 283-285, 1995.
23. O'Byrne, P. M. Exercise-induced bronchoconstriction: elucidating the roles of leukotrienes and prostaglandins. Pharmacotherapy, 17: 31S-38S, 1997.
24. Drazen, J. M., and Austen, K. F. Leukotrienes and airway responses. Am. Rev. Respir. Dis., 136: 985-998, 1987.
25. Funk, C. D. The molecular biology of mammalian lipoxygenases and the quest for eicosanoid functions using lipoxygenase-deficient mice. Biochim. Biophys. Acta, 1304: 65-84, 1996.
26. Ochi, K., Yoshimoto, T., Yamamoto, S., Taniguchi, K., and Miyamoto, T. Arachidonate 5-lipoxygenase of guinea pig peritoneal polymorphonuclear leukocytes. J. Biol. Chem., 25: 5754-5758, 1983.
27. Rouzer, C. A., and Samuelsson, B. On the nature of the 5-lipoxygenase reaction in human leukocytes: enzyme purification and requirement for multiple stimulatory factors. Proc. Natl. Acad. Sci. USA, 82: 6040-6044, 1985.
28. Rouzer, C. A., and Kargman, S. Translocation of 5-lipoxygenase to the membrane in human leukocytes challenged with ionophore A23187. J. Biol. Chem., 263: 10980-10988, 1988.
29. Wood, J. W., Evans, J. F., Ethier, D., Scott, S., Vickers, P. J., Hearn, L., Heibein, J. A., Charleson, S., and Singer, I. I. 5-Lipoxygenase and 5-lipoxygenase-activating protein are localized in the nuclear envelope of activated human leukocytes. J. Exp. Med., 178: 1935-1946, 1993.
30. Peters-Golden, M., and McNish, R. W. Redistribution of 5-lipoxygenase and cytosolic phospholipase A2 to the nuclear fraction upon macrophage activation. Biochem. Biophys. Res. Commun., 196: 147-153, 1993.
31. Wong, A., Hwang, S. M., Cook, M. N., Hogaboom, G. K., and Crooke, S. T. Interactions of 5-lipoxygenase with membranes: studies on the association of soluble enzyme with membranes and alterations in enzyme activity. Biochemistry, 27: 6763-6769, 1988.
32. Brock, T. G., McNish, R. W., and Peters-Golden, M. Translocation and leukotriene synthetic capacity of nuclear 5-lipoxygenase in rat basophilic leukemia cells and alveolar macrophages. J. Biol. Chem., 270: 21652-21658, 1995.
33. Woods, J. W., Coffey, M. J., Brock, T. G., Singer, I. I., and Peters-Golden. M. 5-Lipoxygenase is located in the euchromatin of the nucleus in resting human alveolar macrophages and translocates to the nuclear envelope upon cell activation. J. Clin. Invest., 95: 2035-2046, 1995.
34. Mahmud, I., Suzuki, T., Yamamoto, Y., Suzuki, H., Takahashi, Y., Yoshimotc, T., and Yamamoto, S. Induction of cyclooxygenase and suppression of 12-lipoxygenase in human erythroleukemia cells upon phorbol ester-induced differentiation. Biochim. Biophys. Acta, 1166: 211-216, 1993.
35. Chang, W-C., Ning, C-C., Lin, M. T., and Huang, J-D. Epidermal growth factor enhances a microsomal 12-lipoxygenase activity in A431 cells. J. Biol. Chem., 267: 3657-3666, 1992.
36. Baba, A., Sakuma, S., Okamoto, H., Inoue, T., and Iwata, H. Calcium induces membrane translocation of 12-lipoxygenase in rat platelets. J. Biol. Chem., 264: 15790-15795, 1989.
37. 2+-dependent translocation to membranes. Prostaglandins, 46: 471-477, 1993.
38. Nadel, J. A., Conrad, D. J., Ueki, I. F., Schuster, A., and Sigal, E. Immunocytochemical localization of arachidonate 15-lipoxygenase in erythrocytes, leukocytes, and airway cells. J. Clin. Invest., 87: 1139-1145, 1991.
39. Narumiya, S., Salmon, J. A., Cottee, F. H., Weatherley, B. C., and Flower, R. J. Arachidonic acid 15-lipoxygenase from rabbit peritoneal polymorphonuclear leukocytes. J. Biol. Chem., 256: 9583-9592, 1981.
40. Atluru, D., and Goodwin, J. S. Leukotriene B4 causes proliferation of interleukin 2-dependent T cells in the presence of suboptimal levels of interleukin 2. Cell. Immunol., 99: 444-452, 1986.
41. Baud, L., Perez, J., Denis, M., and Ardaillou, R. Modulation of fibroblast proliferation by sulfidopeptide leukotrienes: effect of indomethacin. J. Immunol., 138: 1190-1195, 1987.
42. Kragballe, K., Desjarlais, L., and Voorhees, J. J. Leukotrienes B4, C4 and D4 stimulate DNA synthesis in cultured human epidermal keratinocytes. Br. J. Dermatol., 113: 43-52, 1985.
43. Baud, L., Sraer, J., Perez, J., Nivez, M-P., and Ardaillou, R. Leukotriene C4 binds to human glomerular epithelial cells and promotes their proliferation in vitro. J. Clin. Invest, 76: 374-377, 1985.
44. Palmberg, L., Lindgren, J. A., Thyberg, J., and Claesson, H-E. On the mechanism of induction of DNA synthesis in cultured arterial smooth muscle cells by leukotrienes. Possible role of prostaglandin endoperoxide synthase producs and platelet-derived growth factor. J. Cell Sci., 98: 141-149, 1991.
45. Leikauf, G. D., Claesson. H-E., Doupnik, C. A., Hybbinette, S., and Grafstrom, R. C. Cysteinyl leukotrienes enhance growth of human airway epithelial cells. Am. J. Pathol., 259: L255-L261, 1989.
46. Yamaoka, K. A., Claesson, H-E., and Rosen, A. Leukotriene B4 enhances activation, proliferation, and differentiation of human B lymphocytes. J. Immunol., 143: 1996-2000, 1989.
47. Snyder, D. S. Antiproliferative effects of lipoxygenase inhibitors on human leukemia cells. Adv. Prostaglandin Thromboxane Leukotriene Res., 21B: 921-924, 1991.
48. Snyder, D. S., and Desforges, J. F. Lipoxygenase metabolites of arachidonic acid modulate hematopoiesis. Blood, 67: 1675-1679, 1986.
49. Miller, A. M., Weiner, R. S., and Ziboh, V. A. Evidence for the role of leukotrienes C4 and D4 as essential intermediates in CSF-stimulated human myeloid colony formation. Exp. Hematol., 14: 760-765, 1986.
50. Ziboh, V. A., Wong, T., Wu, M-C., and Yunis, A. A. Modulation of colony stimulating factor-induced murine myeloid colony formation by S-peptido-lipoxygenase products. Cancer Res., 46: 600-603, 1986.
51. Yamamoto, S. Mammalian lipoxygenases: molecular structures and functions. Biochim. Biophys. Acta, 1128: 117-131, 1992.
52. Takahashi, Y., Ueda, N., and Yamamoto, S. Two immunologically and catalytically distinct arachidonate 12-lipoxygenases of bovine platelets and leukocytes. Arch. Biochem. Biophys., 266: 613-621, 1988.
53. Walstra, P., Verhagen, J., Vermeer, M. A., Veldink, G. A., and Vliegenthart, J. F. G. Demonstration of a 12-lipoxygenase activity in bovine polymorphonuclear leukocytes. Biochim. Biophys. Acta, 921: 312-319, 1987.
54. Funk, C. D., Furci, L., and Fitzgerald, G. A. Molecular cloning, primary structure, and expression of the human platelet/erythroleukemia cell 12-lipoxygenase. Proc. Natl. Acad. Sci. USA, 87: 5638-5642, 1990.
55. Hada, T., Ueda, N., Takahashi, Y., and Yamamoto, S. Catalytic properties of human platelet 12-lipoxygenase as compared with the enzymes of other origins. Biochim. Biophys. Acta, 1083: 89-93, 1991.
56. De Marzo, N., Sloane, D. L., Dicharry, S., Highland, E., and Sigal, E. Cloning and expression of an airway epithelial 12-lipoxygenase. Am. J. Physiol., 202: L198-L207, 1992.
57. Watanabe, T., Medina, J. F., Haeggstrom, J. Z., Radmark, O., and Samuelsson, B. Molecular cloning of a 12-lipoxygenase cDNA from rat brain. Eur. J. Biochem., 212: 605-612, 1993.
58. Yamamoto, S., Suzuki, H., and Ueda, N. Arachidonate 12-lipoxygenases. Prog. Lipid Res., 36: 23-41, 1997.
59. Funk, C. D., Funk, L. B., FitzGerald, G. A., and Samuelsson, B. Characterization of human 12-lipoxygenase genes. Proc. Natl. Acad. Sci. USA, 89: 3962-3966, 1992.
60. Yoshimoto, T., and Yamamoto, S. Arachidonate 12-lipoxygenase. J. Lipid Mediat. Cell Signal., 12: 195-212, 1995.
61. Toh, H., Yokoyama, C., Tanabe, T., Yoshimoto, T., and Yamamoto, S. Molecular evolution of cyclooxygenase and lipoxygenase. Prostaglandins, 44: 291-315, 1992.
62. Nguyen, T., Falgueyret, J-P., Abramovitz, M., and Riendeau, D. Evaluation of the role of conserved his and met residues among lipoxygenases by site-directed mutagenesis of recombinant human 5-lipoxygenase. J. Biol. Chem., 266: 22057-22062, 1991.
63. Zhang, Y. Y., Radmark, O., and Samuelsson, B. Mutagenesis of some conserved residues in human 5-lipoxygenase: effects on enzyme activity. Proc. Natl. Acad. Sci. USA, 89: 485-489, 1992.
64. Schafer, A. I. Deficiency of platelet lipoxygenase activity in myeloproliferative disorders. N. Engl. J. Med., 306: 381-386, 1982.
65. Matsuda, S., Murakami, J., Yamamoto, Y., Konishi, Y., Yokoyama, C., Yoshimoto, T., Yamamoto, S., Mimura, Y., and Okuma, M. Decreased messenger RNA of arachidonate 12-lipoxygenase in platelets of patients with myeloproliferative disorders. Biochim. Biophys. Acta, 1180: 243-249, 1993.
66. Chang, W-C., Liu, Y-W., Ning, C-C., Suzuki, H., Yoshimoto, T., and Yamamoto, S. Induction of arachidonate 12-lipoxygenase mRNA by epidermal growth factor in A431 cells. J. Biol. Chem., 268: 18734-18739, 1993.
67. Conrad, D. J., Kuhn, H., Mulkins, M., Highland, E., and Sigal, E. Specific inflammatory cytokines regulate the expression of human monocyte 15-lipoxygenase. Proc. Natl. Acad. Sci. USA, 89: 217-221, 1992.
68. Nassar, G. M., Morrow, J. D., Roberts, L. J., II, Lakkis, F. G., and Badr, K. F. Induction of 15-lipoxygenase by interleukin-13 in human blood monocytes. J. Biol. Chem., 269: 27631-27634, 1994.
69. Moody, T. R., Leyton, J., Martinez, A., Hong, S., Malkinson, A., and Mulshine, J. L. Lipoxygenase inhibitors prevent lung carcinogenesis and inhibit non-small cell lung cancer growth. Exp. Lung Res., 24: 617-628, 1998.
70. Rioux, N., and Castonguay, A. Inhibitors of lipoxygenase: a new class of cancer chemopreventive agents. Carcinogenesis (Lond.), 19: 1393-1400, 1998.
71. Avis, I. M., Jett, M., Boyle, T., Vos, M. D., Moody, T., Treston, A. M., Martinez, A., and Mulshine, J. L. Growth control of lung cancer by interruption of 5-lipoxygenase-mediated growth factor signaling. J. Clin. Invest., 97: 806-813, 1996.
72. Kulkarni, A. P., Cai, Y., and Richards, I. S. Rat pulmonary lipoxygenase: dioxygenase activity and role in xenobiotic metabolism. Int. J. Biochem., 24: 255-261, 1992.
73. Nemoto, N., and Takayama, S. Arachidonic acid-dependent activation of benzo[a]pyrene to bind to proteins with cytosolic and microsomal fractions from rat liver and lung. Carcinogenesis (Lond.), 5: 961-964, 1984.
74. Hunter, J. A., Finkbciner, W. E., Nadel, J. A., Goetzl, E. J., and Holtzman, M. J. Predominant generation of 15-lipoxygenase metabolites of arachidonic acid by epithelial cells from human traehea. Proc. Natl. Acad. Sci. USA. 82: 4633-4637, 1985.
75. Kumlin, M., and Dahlen, S-E. Characteristics of formation and further metabolism of leukotrienes in the chopped human lung. Biochim. Biophys. Acta. 1044: 201-210, 1990.
76. Chaudry, A., McClinton, S., Moffat, L. E. F., and Wahle, K. W. J. Essential fatty acid distribution in the plasma and tissue phospholipids of patients with benign and malignant prostatic disease. Br. J. Cancer. 64: 1157-1160, 1991.
77. Chaudry, A. A., Wahle, K. W. J., McClinton, S., and Moffat, L. E. F. Arachidonic acid metabolism in benign and malignant prostalic tissue in vitro: effects of fatty acids and cyclooxygenase inhibitors. Int. J. Cancer, 57: 176-180, 1994.
78. Rose, P., and Connolly, J. M. Effects of fatty acids and eicosanoid synthesis inhibitors on the growth of two human prostate cancer cell lines. Prostate, 18: 243-254, 1991.
79. Drago, J. R., and Al-Mondhiry, H. A. B. The effect of prostaglandin modulators on prostate tumor growth and metastasis. Anticancer Res., 4: 391-394, 1984.
80. Tazume, S., and Pollard, M. The relationship between natural killer cells and drugs that modify metastasis of PA-III cells. Cancer Lett., 29: 323-329, 1985.
81. Ablin, R. J., and Shaw, M. W. Prostaglandin modulation of prostate tumor growth and metastases. Anticancer Res., 6: 327-328, 1986.
82. Anderson, K. M., Wygodny, J. B., Ondrey, F., and Harris, J. Human PC-3 prostate cell line DNA synthesis is suppressed by eicosatetraynoic acid, an in vitro inhibitor of arachidonic acid metabolism. Prostate, 12: 3-12, 1988.
83. Anderson, K. M., Seed, T. M., Wilson, D. E., and Harris, J. E. 5,8,11,14-Eicosatetraynoic acid-induced destruction of mitochondria in human prostate cells (PC-3). In Vitro Cell. Dev. Biol., 28A: 410-414, 1992.
84. Anderson, K. M., Seed, T., Ondrey, F., and Harris, J. E. The selective 5-lipoxygenase inhibitor A63162 reduces PC3 proliferation and initiates morphologic changes consistent with secretion. Anticancer Res., 14: 1951-1960, 1994.
85. Mohler, J. L. Cellular motility and proslatic carcinoma metastases. Cancer Metastasis Rev., 12: 53-67, 1993.
86. Mohler, J. L., Partin, A. W., and Coffey, D. S. Prediction of metastatic potential by a new grading system of cell motility: validation in the Dunning R-3327 prostatic adenocarcinoma model. J. Urol., 138: 168-170, 1987.
87. Albini, A., Iwamoto, Y., Kleinman, H. K., Martin, G. R., Aaronson, S. A., Kozlowski, J. M., and McEwan, R. N. A rapid in vitro assay for qantitating the invasive potential of tumor cells. Cancer Res., 47: 3239-3245, 1987.
88. Timar, J., Tang, D., Bazaz, R., Haddad, M. M., Kimler, V. A., Taylor, J. D., and Honn, K. V. PKC mediates 12(S)-HETE-induced cytoskeletal rearrangement in B16a melanoma cells. Cell Motil. Cytoskeleton, 26: 49-65, 1993.
89. Crooke, S. T., Mattern, M., Sarau, H. M., Winkler, J. D., Balcarek, J., Wong, A., and Bennett, C. F. The signal transduction system of the leukotriene D4 receptor. Trends Pharmacol. Sci., 10: 103-107, 1989.
90. Sumida, C., Graber, R., and Nunez, E. Role of fatty acids in signal transduction: modulators and messengers. Prostaglandins Leukotrienes Essent. Fatty Acids, 48: 117-122, 1993.
91. Hansson, A., Serhan, C. N., Haeggstrom, J., Ingelman-Sundberg, M., and Samuelsson, B. Activation of protein kinase C by lipoxin A and other eicosanoids. Intracellular action of oxygenation products of arachidonic acid. Biochem. Biophys. Res. Commun., 134: 1215-1222, 1986.
92. 2+. FEBS Lett., 192: 189-193, 1985.
93. Ware, J. L. Growth factors and their receptors as determinants in the proliferation and metastasis of human prostate cancer. Cancer Metastasis Rev., 12: 287-301, 1993.
94. Thompson, T. C. Growth factors and oncogenes in prostate cancer. Cancer Cells, 2: 345-354, 1990.
95. Karmali, R. A. Eicosanoids in breast cancer. Eur. J. Cancer Clin. Oncol., 23: 5-7, 1987.
96. Fischer, S. M., Conti, C. J., Locniskar, M., Belury, M. A., Maldve, R. E., Lee, M. L., Leyton, J., Slaga, T. J., and Bechtel, D. H. The effect of dietary fat on the rapid development of mammary tumors induced by 7,12-dimethylhenz(a)anthracene in SENCAR mice. Cancer Res., 52: 662-666, 1992.
97. Welsch, C. W. Relationship between dietary fat and experimental mammary tumorigenesis: a review and critique. Cancer Res., 52: 2040S-2048S, 1992.
98. Dao, T. L., and Hilf, R. Dietary fat and breast cancer: a search for mechanisms. Adv. Exp. Med. Biol., 322: 223-237, 1992.
99. Cohen, L. A., Thompson, D. O., Maeura, Y., Choi, K., Blank, M. E., and Rose, D. P. Dietary fat and mammary cancer. I. Promoting effects of different dietary fats on N-nitrosomethylurea-induced rat mammary tumorigenesis. J. Natl. Cancer Inst.. 77: 33-42, 1986.
100. Cave, W. T., Jr. Dietary n-3 (ω-3) polyunsaturated fatty acid effects on animal tumorigenesis. FASEB J., 5: 2160-2166, 1991.
101. Abou-El-Ela, S. H., Prasse, K. W., Carroll, R., Wade, A. E., Dharwadkar, S., and Bunce, O. R. Eicosanoid synthesis in 7,12-dimethylbenz(a)anthracene-induced mammary carcinomas in Sprague-Dawley rats fed primrose oil, menhaden oil or corn oil diet. Lipids, 23: 948-954, 1988.
102. Kort, W. J., Bijma, A. M., van Dam, J. J., van der Ham, A. C., Hekking, J. M., van der Ingh, H. F., Meijer, W. S., van Wilgenburg, M. G. M., and Zijlstra, F. J. Eicosanoids in breast cancer patients before and after mastectomy. Prostaglandins Leukotrienes Essent. Fatty Acids. 45: 319-327, 1992.
103. Natarajan, R., Esworthy, R., Bai, W., Gu, J-L., Wilczynski, S., and Nadler, J. Increased 12-lipoxygenase expression in breast cancer tissues and cells. Regulation by epidermal growth factor. J. Clin. Endocrinol. Metab., 82: 1790-1798, 1997.
104. Liu, X-H., Connolly, J. M., and Rose, D. P. Eicosanoids as mediators of linoleic acid-stimulated invasion and type IV collagenase production by a metastalic human breast cancer cell line. Clin. Exp. Metastasis, 14: 145-152, 1996.
105. Rose, D. P., and Connolly, J. M. Stimulation of growth of human breast cancer cell lines in culture by linoleic acid. Biochem. Biophys. Res. Commun., 164: 277-283, 1989.
106. Rose, D. P., and Connolly, J. M. Effects of fatty acids and inhibitors of eicosanoid synthesis on the growth of a human breast cancer cell line in culture. Cancer Res., 50: 7139-7144, 1990.
107. Hubbard, N. E., Chapkin, R. S., and Erickson, K. L. Inhibition of growth and linoleate-enhanced metastasis of a transplantable mouse mammary tumor by indomethacin. Cancer Lett., 43: 111-120, 1988.
108. Fulton, A. M. In vivo effects of indomethacin on the growth of murine mammary tumors. Cancer Res., 44: 2416-2420, 1984.
109. McCormick, D. L., and Moon, R. C. Inhibition of mammary carcinogenesis by flurbiprofen, a non-steroidal antiinflammatory agent. Br. J. Cancer, 48: 859-861, 1983.
110. Feldman, J. M., and Hilf, R. Failure of indomethacin to inhibit growth of the R3230AC mammary tumor in rats. J. Natl. Cancer Inst., 75: 751-756, 1985.
111. Abou-El-Ela, S. H., Prasse, K. W., Farrell, R. L., Carroll, R. W., Wade, A. E., and Bunce, O. R. Effects of DL-2-difluoromethylornithine and indomethacin on mammary tumor promotion in rats fed high n-3 and/or n-6 fat diets. Cancer Res., 49: 1434-1440, 1989.
112. Buckman, D. K., Hubbard, N. E., and Erickson, K. L. Eicosanoids and linoleate-enhanced growth of mouse mammary tumor cells. Prostaglandins Leukotrienes Essent. Fatty Acids, 44: 177-184, 1991.
113. Fulton, A. M, Effects of indomethacin on the growth of cultured mammary tumors. Int. J. Cancer, 33: 375-379, 1984.
114. McCormick, D. L., and Spicer, A. M. Nordihydroguaiaretic acid suppression of rat mammary carcinogenesis induced by N-methyl-N-nitrosourea. Cancer Lett., 37: 139-146, 1987.
115. Noguchi, M., Kitagawa, H., Miyazaki, I., and Mizukami, Y. Influence of esculetin on incidence, proliferation, and cell kinetics of mammary carcinomas induced by 7,12-dimethylbenz[a]anthracene in rats on high- and low-fat diets. Jpn. J. Cancer Res., 84: 1010-1014, 1993.
116. Kitagawa, H., and Noguchi, M. Comparative effects of piroxicam and esculetin on incidence, proliferation, and cell kinetics of mammary carcinomas induced by 7,1 2-dimethylbenz[a]anthracene in rats on high- and low-fat diets. Oncology. 51: 401-410, 1994.
117. Matsunaga, K., Yoshimi, N., Yamada, Y., Shimizu, M., Kawabata, K., Ozawa, Y., Hara, A., and Mori, H. Inhibitory effects of nabumetone, a cyclooxygenase-2 inhibitor, and esculetin, a lipoxygenase inhibitor, on N-methyl-N-nitrosourea-induced mammary carcinogenesis in rats. Jpn. J. Cancer Res., 89: 496-501, 1998.
118. Liu, X-H., Connolly, J. M., and Rose, D. P. The 12-lipoxygenase genetransfected MCF-7 human breast cancer cell line exhibits estrogen-independent, but estrogen and omega-6 fatty acid-stimulated proliferation in vitro, and enhanced growth in athymic nude mice. Cancer Lett., 109: 223-230, 1996.
119. Reddy, N., Everhart, A., Eling, T., and Glasgow, W. Characterization of a 15-lipoxygenase in human breast carcinoma BT-20 cells: stimulation of 13-HODE formation by TGFα/EGF. Biochem. Biophys. Res. Commun., 231: 111-116, 1997.
120. Jardines, L., Weiss, M., Fowble, B., and Greene, M. neu (c-erbB-2/HER2) and the epidermal growth factor receptor (EGFR) in breast cancer. Pathobiology, 61: 268-282, 1993.
121. Fox, S. B., Smith, K., Hollyer, J., Greenall, M., Hastrich, D., and Harris, A. L. The epidermal growth factor receptor as a prognostic marker: results of 370 patients and review of 3009 patients. Breast Cancer Res. Treat., 29: 41-49, 1994.
122. Zhuang, Z-P., Vortmeyer, A. O., Mark, E. J., Odze, R., Emmert-Buck, M. R., Merino, M. J., Moon, H., Liotta, L. A., and Duray, P. H. Barrett's esophagus: metaplastic cells with loss of heterozygosity at the APC gene locus are clonal precursors to invasive adenocarcinoma. Cancer Res., 56: 1961-1964, 1996.
123. Rose, D. P., Connolly, J. M., and Liu, X-H. Effects of linoleic acid on the growth and metastasis of two human breast cancer cell lines in nude mice and the invasive capacity of these cell lines in vitro. Cancer Res., 54: 6557-6562, 1994.
124. Rose, D., and Connolly, J. M. Effects of dietary ω-3 fatty acids on human breast cancer growth and metastases in nude mice. J. Natl. Cancer Inst., 85: 1743-1747, 1993.
125. Johanning, G. L., and Lin, T-Y. Unsaturated fatty acid effects on human breast cancer cell adhesion. Nutr. Cancer, 24: 57-66, 1995.
126. Rigas, B., Goldman, I. S., and Levine, L. Altered eicosanoid levels in human colon cancer. J. Lab. Clin. Med., 122: 518-523, 1993.
127. Bortuzzo, C., Hanif, R., Kashfi, K., Staiano-Coico, L., Sniff, S. J., and Rigas, B. The effect of leukotrienes B and selected HETEs on the proliferation of colon cancer cells. Biochim. Biophys. Acta, 1300: 240-246, 1996.
128. Hussey, H. J., and Tisdale, M. J. Inhibition of tumour growth by lipoxygenase inhibitors. Br. J. Cancer, 74: 683-687, 1996.
129. Cortese, J. F., Spannhake, E. W., Eisinger, W., Potter, J. J., and Yang, V. W. The 5-lipoxygenase pathway in cultured human intestinal epithelial cells. Prostaglandins, 49: 155-166, 1995.
130. Sjolander, A., Schippert, A., and Hammarstrom, S. A human epithelial cell line. intestine-407, can produce 5-hydroxyeicosatetraenoic acid and leukotriene B4. Prostaglandins, 45: 85-96, 1993.
131. Dias, V. C., Wallace, J. L., and Parsons, H. G. Modulation of cellular phospholipid fatty acids and leukotriene B4 synthesis in the human intestinal cell (CaCo-2). Gut, 33: 622-627, 1992.
132. Craven, P. A., and DeRubertis, F. R. Profiles of eicosanoid production by superficial and proliferative colonic epithelial cells and sub-epithelial colonic tissue. Prostate, 32: 387-399, 1986.
133. Gao, X., and Honn, K. V. Biological properties of 12(S)-HETE in cancer metastasis. Adv. Prostaglandin Thromboxane Leukotriene Res., 23: 439-444, 1995.
134. Krieg, P., Kinzig, A., Ress-Loschke, M., Vogel, S., Vanlandingham, B., Stephan, M., Lehmann, W-D., Marks, F., and Furstenberger, G. 12-Lipoxygenase isoenzymes in mouse skin tumor development. Mol. Carcinog., 14: 118-129, 1995.
135. Takahashi, Y. Reddy, G. R., Ueda, N., Yamamoto, S., and Arase, S. Arachidonate 12-lipoxygenase of platelet-type in human epidermal cells. J. Biol. Chem., 268: 16443-16448, 1993.
136. Liu, Y-W., Asaoka, Y., Suzuki, H., Yoshimoto, T., Yamamoto, S., and Chang, W-C. Induction of 12-lipoxygenase expression by epidermal growth factor is mediated by protein kinase C in A431 cells. J. Pharmacol. Exp. Ther., 271: 567-573, 1994.
137. Chen, B-K., Liu, Y-W., Yamamoto, S., and Chang, W-C. Overexpression of Ha-ras enhances the transcription of human arachidonate 12-lipoxygenase promoter in A431 cells. Biochim. Biophys. Acta, 1344: 270-277, 1997.
138. El Attar, T. M. A., Lin, H. S., and Vanderhoek, J. Y. Biosynthesis of prostaglandins and hydroxy fatty acids in primary squamous carcinomas of head and neck in humans. Cancer Lett., 27: 255-259, 1985.
139. Liu, B., Marnett, L. J., Chaudhary, A., Ji, C., Blair, I. A., Johnson, C. R., Diglio, C. A., and Honn, K. V. Biosynthesis of 12(S)-hydroxyeicosatetraenoic acid by B16 amelanotic melanoma cells is a determinant of their metastatic potential. Lab. Invest., 70: 314-323, 1994.
140. Anderson, K. M., Levin, J., Jajeh, A., Seed, T., and Harris, J. E. Induction of apoptosis in blood cells from a patient with acute myelogenous leukemia by SC41661A, a selective inhibitor of 5-lipoxygenase. Prostaglandins Leukotrienes Essent. Fatty Acids, 48: 323-326, 1993.
141. Anderson, K. M., Seed, T., Jajeh, A., Dudeja, P., Byun, T., Meng, J., Ou, D., Bonomi, P., and Harris, J. E. An in vivo inhibitor of 5-lipoxygenase, MK886. at micromolar concentration induces apoptosis in U937 and CML cells. Anticancer Res., 16: 2589-2599, 1996.
142. Stenke, L., Samuelsson, J., Palmblad, J., Dabrowski, L., Reizenstein, P., and Lindgren, J. A. Elevated white blood cell synthesis of leukotriene C4 in chronic myelogenous leukaemia but not in polycynthaemia vera. Br. J. Haematol., 74: 257-263, 1990.
143. Anderson, K. M., Seed, T., Plate, J. M. D., Jajeh, A., Meng, J., and Harris, J. E. Selective inhibitors of 5-lipoxygenase reduce CML blast cell proliferation and induce limited differentiation and apoptosis. Leuk. Res., 19: 789-801, 1995.
144. Snyder, D. S., Castro, R., and Desforges, J. F. Antiproliferative effects of lipoxygenase inhibitors on malignant human hematopoietic cell lines. Exp. Hematol., 17: 6-9, 1989.
145. Brooks, C. D. W., and Summers, J. B. Modulators of leukotriene biosynthesis and receptor activation. J. Med. Chem. 39: 2629-2654, 1996.
146. Carter, G. W., Young, P. R., Albert, D. H., Bouska, J., Dyer, R., Bell, R. L., Summers, J. B., and Brooks, D. W. 5-Lipoxygenase inhibitory activity of Zileuton, J. Pharmacol. Exp. Ther., 256: 929-937, 1991.
147. Read, N. G., Astbury, P. J., Evans, G. O., Goodwill, D. A., and Rowlands, A. Nephrotic syndrome associated with N-hydroxyureas, inhibitors of 5-lipoxygenase. Arch. Toxicol., 69: 480-490, 1995.
148. Bell, R. L., Brooks, D. W., Young, P. R., Lanni, C., Stewart, A. O., Bouska, J., Malo, P. E., and Carter, G. W. A-78773: a selective, potent 5-lipoxygenase inhibitor. J. Lipid Mediat., 6: 259-264, 1993.
149. Brooks, C. D. W., Stewart, A. O., Basha, A., Bhatia, P., Ratajczyk, J. D., Martin, J. G., Craig, R. A., Kolasa, T., Bouska, J. B., Lanni, C., Harris, R. R., Malo, P. E., Carter, G. W., and Bell, R. L. (R)-(+)-N-[3-[5-[(4-fluorophenyl)-methyl]-2-thienyl]-1-methyl-2-propynyl]-N- hydroxyurea (ABT-761), a second-generation 5-lipoxygenase inhibitor. J. Med. Chem., 38: 4768-4775, 1995.
150. Nakadate, T., Yamamoto, S., Aizu, E., and Kato, R. Inhibition of mouse epidermal 12-lipoxygenase by 2,3,4-trimethyl-6-(12-hydroxy-5,10-dodecadiy-nyl)-1,4-benzoquinone (AA861). J. Pharm. Pharmacol., 37: 71-73, 1985.
151. Aizu, E., Nakadate, T., Yamamoto, S., and Kato, R. Inhibition of 12-0-tetradecanoylphorbol-13-acetate-mediated epidermal ornithine decarboxylase induction and skin tumor promotion by new lipoxygenase inhibitors lacking protein kinase C inhibitory effects. Carcinogenesis (Lond.), 7: 1809-1812, 1986.
152. Uzumaki, H., Yamamoto, S., and Kato, R. Effects of lipoxygenase and cyclooxygenase inhibitors on the induction of ornithine decarboxylase by 12-0-tetradecanoylphorbol-13-acetate and isoproterenol in mouse tissues in vivo. Carcinogenesis (Lond.), 7: 289-294, 1986.
153. Tsukada, T., Nakashima, K., and Shirakawa, S. Arachidonate 5-lipoxygenase inhibitors show potent antiproliferative effects on human leukemia cell lines. Biochem. Biophys. Res. Commun., 140: 832-836, 1986.
154. Ralph, R. K., and Wojcik, S. Inhibitors of lipoxygenase have antiproliferative effects on P815 murine mastocytoma cells. Cancer Lett., 49: 181-185, 1990.
155. Tang, D. G., Chen, Y. Q., and Honn, K. V. Arachidonate lipoxygenases as essential regulators of cell survival and apoptosis. Proc. Natl. Acad. Sci. USA, 93: 5241-5246, 1996.
156. Crawley, G. C., Dowell, R. I., Edwards, P. N., Foster, S. J., McMillan, R. M., Walker, E. R. H., and Waterson, D. Methoxytetrahydropyrans. A new series of selective and orally potent 5-lipoxygenase inhibitors. J. Med. Chem., 35: 2600-2609, 1992.
157. Gillard, J., Ford-Hutchinson, A. W., Chan, C., Charleson, S., Denis, D., Foster, A., Fortin, R., Leger, S., McFarlane, C. S., Morton, H., Piechuta, H., Riendeau, D., Rouzer, C. A., Rokach, J., Young, R., MacIntyre, D. E., Peterson. L., Bach. T., Eiermann, G., Hopple, S., Humes, J., Hupe, L., Luell, S., Metzger, J., Meurer, R., Miller, D. K., Opas, E., and Pacholok, S. L-663.536 (MK-886) (3-[1-(4-chlorobenzyl)-3-t-butyl-thio-5-isopropylindol-2-yl]-2,2- dimethylpropanoic acid), a novel, orally active leukotriene biosynthesis inhibitor. Can. J. Physiol. Pharmacol., 67: 456-464, 1989.
158. Ford-Hutchinson, A. W., Gresser, M., and Young, R. N. 5-Lipoxygenase. Annu. Rev. Biochem., 63: 383-417, 1994.
159. Bel, E. H., Tanaka, W., Spector, R., Friedman, B., von de Veen, H., Dijkman, J. H., and Sterk, P. J. MK-886, an effective oral leukotriene biosynthesis inhibitor on antigen-induced early and late asthmatic reactions in man. Am. Rev. Respir. Dis., 141: A31, 1990.
160. Prasit, P., Belley, M., Blouin, M., Brideau, C., Chan, C., Charleson, S., Evans, J. F., Frenette, R., Gauthier, J. Y., Guay, J., Gillard, J. W., Grimm, E., Ford-Hutchinson, A. W., Hutchinson, J, H., Fortin, R., Jones, T. R., Mancini, J., Leger, S., McFarlane, C. S., Piechuta, H., Riendeau, D., Roy, P., Tagari, P., Vickers, P. J., Young, R. N., and Zamboni, R. A new class of leukotriene biosynthesis inhibitor: the development of MK-0591. J. Lipid Mediat., 6: 239-244, 1993.
161. Hatzelmann, A., Fruchtmann, R., Mohrs, K. H., Raddatz, S., and Muller-Peddinghaus, R. Mode of action of the new selective leukotriene synthesis inhibitor BAY X-1005 ((R)-2-[4-(quinolin-2-yl-methoxy)phenyl]-2-cyclopentyl acetic acid) and structurally related compounds. Biochem. Pharmacol., 45: 101-111, 1993.
162. Muller-Peddinghaus, R., Fruchtmann, R., Ahr, H-J., Beckermann, B., Buhner, K., Fugmann, B., Junge, B., Matzke, M., Kohlsdorfer, C., Raddatz, S.,
163. Fruchtmann, R., Mohrs, K. H., Hatzelmann, A., Raddatz, S., Fugmann, B., Junge, B., Horstmann, H., and Muller-Peddinghaus, R. In vitro pharmacology of BAY X1005, a new inhibitor of leukotriene synthesis. Agents Actions, 38: 188-195, 1993.
164. Hatzelmann, A., Fruchtmann, R., Mohrs, K. H., Raddatz, S., Matzke, M., Pleiss, U., Keldenich, J., and Muller-Peddinghaus, R. Mode of action of the leukotriene synthesis (FLAP) inhibitor BAY X 1005: implications for biological regulation of 5-lipoxygenase. Agents Actions, 43: 64-68, 1994.
165. Djuric, S. W., Collins, P. W., Jones, P. H., Shone, R. L., Tsai, B. S., Fretland, D. J., Butchko, G. M., Villani-Price, D., Keith, R. H., Zemaitis, J. M., Metcalf, L., and Bauer, R. F. 7-[3-(4-Acetyl-3-methoxy-2-propylphe-noxy)propoxy]-3,4-dihydro-8-propyl-2H-1- benzopyran-2-carboxylic acid: an orally active selective leukotriene B4 receptor antagonist. J. Med. Chem., 32: 1145-1147, 1989.
166. Tsai, B. S., Villani-Price, D., Keith, R. H., Zemaitis, J. M., Bauer, R. F., Leonard, R., Djuric, S. W., and Shone, R. L. SC-41930: an inhibitor of leukotriene B4-stimulated human neutrophil functions. Prostaglandins, 38: 655-674, 1989.
167. Penning, T. D., Djuric, S. W., Miyashiro, J. M., Yu, S., Snyder, J. P., Spangler, D., Anglin, C. P., Frelland, D. J., Kachur, J. F., Keith, R. H., Tsai, B. S., Villani-Price, D., Walsh, R. E., and Widomski, D. L. Second-generation leukotriene B4 receptor antagonists related to SC-41930: heterocyclic replacement of the methyl ketone pharmacophore. J. Med. Chem., 38: 858-868, 1995.
168. Tsai, B. S., Keith, R. H., Villani-Price, D., Kachur, J. F., Yang, D. C., Djuric, S. W., and Yu, S. The in vitro pharmacology of SC-51146: a potent antagonist of leukotriene B4 receptors. J. Pharmacol. Exp. Ther., 268: 1499-1505, 1994.
169. Djuric, S. W., Docter, S. H., Yu, S. S., and Spangler, D. Synthesis and pharmacological activity of SC-53228, a leukotriene B4 receptor antagonist with high intrinsic potency and selectivity. Bioorg. Med. Chem. Lett., 4: 811-816, 1994.
170. Krell, R. D., Aharony, D., Buckner, C. K., Keith, R. A., Kusner, E. J., Snyder, D. W., Bernstein, P. R., Matassa, V. G., Yee, Y. K., Brown, F. J., Hesp, B., and Giles, R. E. The preclinical pharmacology of ICI 204,219: a peptide leukotriene antagonist. Am. Rev. Respir. Dis., 141: 978-987, 1990.
171. F-D-C Reports. FDA reform should focus on consensus issues first, Rep. Fox urges house leadership. Commerce committee may produce several separate bills. FDC Reports (The Pink Sheet), 58: 3, 1996.
172. Sekiya, K., Okuda, H., and Arichi, S. Selective inhibition of platelet lipoxygenase by esculetin. Biochim. Biophys. Acta, 713: 68-72, 1982.
173. Neichi, T., Koshihara, Y., and Murota, S-I. Inhibitory effect of esculetin on 5-lipoxygenase and leukotriene biosynthesis. Biochim. Biophys. Acta, 753: 130-132, 1983.
174. Panossian, A. G. Inhibition of arachidonic acid 5-lipoxygenase of human polymorphonuclear leukocytes by esculetin. Biochim. Biophys. Acta, 43: 1351-1355, 1984.
175. Kimura, Y., Okuda, H., Arichi, S., Baba, K., and Kozawa, M. Inhibition of the formation of 5-hydroxy-6,8,11,14-eicosatetraenoic acid from arachidonic acid in polymorphonuclear leukocytes by various coumarins. Biochim. Biophys. Acta, 834: 224-229, 1985.
176. Tubaro, A., Del Negro, P., Ragazzi, E., Zampiron, S., and Loggia, R. D. Anti-inflammatory and peripheral analgesic activity of esculetin in vivo. Pharmacol. Res. Commun., 20: 83-85, 1988.
177. Earashi, M., Noguchi, M., Kinoshita, K., and Tanaka, M. Effects of eicosanoid synthesis inhibitors on the in vitro growth and prostaglandin E and leukotriene B secretion of a human breast cancer cell line. Oncology, 52: 150-155, 1995.
178. Huang, H-C., Hsieh, L-M., Chen, H-W., Lin, Y-S., and Chen, J-S. Effects of baicalein and esculetin on transduction signals and growth factors expression in T-lymphoid leukemia cells. Eur. J. Pharmacol., 268: 73-78, 1994.
179. Huang, H-C., Lai, M-W., Wang, H-R., Chung, Y-L., Hsieh, L-M., and Chen, C-C. Antiproliferative effect of esculetin on vascular smooth muscle cells. Possible roles of signal transduction pathways. Eur. J. Pharmacol., 237: 39-44, 1993.
180. Reich, R., and Martin, G. R. Identification of arachidonic acid pathways required for the invasive and metastatic activity of malignant tumor cells. Prostaglandins, 51: 1-17, 1996.
181. Sekiya, K., and Okuda, H. Selective inhibition of platelet lipoxygenase by baicalein. Biochem. Biophys. Res. Commun., 105: 1090-1095, 1982.
182. Butenko, I. G., Gladtchenko, S. V., and Galushko, S. V. Anti-inflammatory properties and inhibition of leukotriene C4 biosynthesis in vitro by flavonoid baicalein from Scutellaria baicalensis Georgy roots. Agents Actions, 39: C49-C51, 1993.
183. Motoo, Y., and Sawabu, N. Antitumor effects of saikosaponins, baicalin and baicalein on human hepatoma cell lines. Cancer Lett., 86: 91-95, 1994.
184. Matsuzaki, Y., Kurokawa, N., Terai, S., Matsumura, Y., Kobayashi, N., and Okita, K. Cell death induced by baicalein in hepatocellular carcinoma cell lines. Jpn. J. Cancer Res., 87: 170-177, 1996.
185. Okita, K., Li, Q., Murakamio, T., and Takahashi, M. Anti-growth effects with components of Sho-saiko-to (TJ-9) on cultured human hepatoma cells. Eur. J. Cancer Prev., 2: 169-176, 1993.
186. Li, Q., Okita, K., Murakami, T., and Takahashi, M. Inhibitory effect of baicalein on the growth of cultured hepatoma cells (HuH-7). Biotherapy, 4: 1664-1670, 1990.
187. So, F. V., Guthrie, N., Chambers, A. F., and Carroll, K. K. Inhibition of proliferation of estrogen receptor-positive MCF-7 human breast cancer cells by flavonoids in the presence and absence of excess estrogen. Cancer Lett., 112: 127-133, 1997.
188. Huang, F-C., Shoupe, T. S., Lin, C. J., Lee, T. D. Y., Chan, W-K., Tan, J., Schnapper, M., Suh, J. T., Gordon, R. J., Sonnino, P. A., Sutherland, C. A., Van Inwegen, R. G., and Coutts, S. M. Differential effects of a series of hydroxamic acid derivatives on 5-lipoxygenase and cyclooxygenase from neutrophils and 12-lipoxygenase from platelets and their in vivo effects on inflammation and anaphylaxis. J. Med. Chem., 32: 1836-1842, 1989.
189. Marnett, L. J., Leithauser, M. T., Richards, K. M., Blair, I., Honn, K. V., Yamamoto, S., and Yoshimoto, T. Arachidonic acid metabolism of cytosolic fractions of Lewis lung carcinoma cells. Adv. Prostaglandin Thromboxane Leukotriene Res., 21B: 895-900, 1991.
190. Yaffee, M., Walter, P., Richter, C., and Muller, M. Direct observation of iron-induced conformational changes of mitochondrial DNA by high-resolution field-emission in-lens scanning electron microscopy. Proc. Natl. Acad. Sci. USA, 93: 5341-5346, 1996.
191. Denis, D., Falgueyret, J-P., Riendeau, D., and Abramovitz, M. Characterization of the activity of purified recombinant human 5-lipoxygenase in the absence and presence of leukocyte factors. J. Biol. Chem., 266: 5072-5079, 1991.
192. 2O2 and inhibition by metal ions. Eur. J. Biochem., 210: 109-117, 1992.
193. Rouzer, C. A., and Samuelsson, B. Leukocyte arachidonate 5-lipoxygenase: isolation and characterization. Methods Enzymol., 187: 312-319, 1990.
194. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods, 65: 55-63, 1983.
195. Steele, V. E., Moon, R. C., Lubet, R. A., Grubbs, C. J., Reddy, B. S., Wargovich, M., McCormick, D. L, Pereira, M. A., Crowell, J. A., Bagheri, D., Sigman, C. C., Boone, C. W., and Kelloff, G. J. Preclinical efficacy evaluation of potential chemopreventive agents in animal carcinogenesis models: methods and results from the NCI Chemoprevention Drag Development Program. J. Cell. Biochem., 20: 32-54, 1994.
196. Gullino, P. M., Pettigrew, H. M., and Grantham, F. H. N-Nitrosomethylurea as mammary gland carcinogen in rats. J. Natl. Cancer Inst., 54: 401-414, 1975.
197. McCormick, D. L., Adamowski, C. B., Fiks, A., and Moon, R. C. Lifetime dose-response relationships for mammary tumor induction by a single administration of N-methyl-N-nitrosourea. Cancer Res., 41: 1690-1694, 1981.
198. Moon, R. C., and Mehta, R. G. Chemoprevention of experimental carcinogenesis in animals. Prev. Med., 18: 576-591, 1989.
199. Stoner, G. D. Lung tumors in strain A mice as a bioassay for carcinogenicity of environmental chemicals. Exp. Lung Res., 17: 405-423, 1991.
200. Wattenberg, L. W., Wiedmann, T. S., Estensen, R. D., Zimmerman, C. L., Steele, V. E., and Kelloff, G. J. Chemoprevention of pulmonary carcinogenesis by aerosolized budesonide in female A/J mice. Cancer Res., 57: 5489-5492, 1997.
201. Boone, C. W., Kelloff, G. J., and Malone, W. E. Identification of candidate cancer chemopreventive agents and their evaluation in animal models and human clinical trials: a review. Cancer Res., 50: 2-9, 1990.
202. Reddy, B. S., and Maeura, Y. Tumor promotion by dietary fat in azoxymethane-induced colon carcinogenesis in female F344 rats: influence of amount and source of dietary fat. J. Natl. Cancer, Inst., 72: 745-750, 1984.
203. Bird, R. P. Observation and quantification of aberrant crypts in the murine colon treated with a colon carcinogen: preliminary findings. Cancer Lett., 37: 147-151, 1987.
204. Pereira, M. A., Barnes, L. H., Rassman, V. L., Kelloff, G. V., and Steele, V. E. Use of azoxymethane-induced foci of aberrant crypts in rat colon to identify potential cancer chemopreventive agents. Carcinogenesis (Lond.), 15: 1049-1054, 1994.
205. Pretlow, T. P., Barrow, B. J., Ashton, W. S., O'Riordan, M. A., Pretlow, T. G., Jurcisek, J. A., and Stellato, T. A. Aberrant crypts: putative preneoplastic foci in human colonic mucosa. Cancer Res., 51: 1564-1567, 1991.
206. Leav, I., Ho, S-M., Ofner, P., Merk, F. B., Kwan, P. W-L., and Damassa, D. Biochemical alterations in sex hormone-induced hyperplasia and dysplasia of the dorsolateral prostates of Noble rats. J. Natl. Cancer Inst., 80: 1045-1053, 1988.
207. Noble, R. L. The development of prostatic adenocarcinoma in Nb rats following prolonged sex hormone administration. Cancer Res., 37: 1929-1933, 1977.
208. Bosland, M. C., and Prinsen, M. K. Induction of dorsolateral prostate adenocarcinomas and other accessory sex gland lesions in male Wistar rats by a single administration of N-methyl-N-nitrosourea, 7,12-dimethylbenz[a]anthracene, and 3,2′-dimethyl-4-aminobiphenyl after sequential treatment with cyproterome acetate and testosterone propionate. Cancer Res., 50: 691-699, 1990.
209. Bosland, M. C., Prinsen, M. K., Dirksen, T. J. M., and Spit, B. J. Characterization of adenocarcinomas of the dorsolateral prostate induced in Wistar rats by N-methyl-N-nitrosourea, 7,12-dimethylbenz[a]anthracene, and 3,2′-dimethyl-4-aminobiphenyl, following sequential treatment with cyproterone acetate and testosterone. Cancer Res., 50: 700-709, 1990.
210. Warren, B. S., and Slaga, T. J. Mechanisms of inhibition of tumor progression. Basic Life Sci., 61: 279-289, 1993.
211. DiGiovanni, J. Multistage carcinogenesis in mouse skin. Pharmacol. Ther., 54: 63-128, 1992.
212. diGiovanni, J., Slaga, T. J., and Boutwell, R. K. Comparison of the tumor-initiating activity of 7,12-dimethylbenz[a]anthracene and benzo[a]pyrene in femal: SENCAR and CD-1 mice. Carcinogenesis (Lond.), 1: 381-389, 1980.
213. Hagerman, R. A., Smith, T. J., and Locniskar, M. F. Lipoxygenase metabolites activate protein kinase C. FASEB J., 7: A601, 1993.
214. Solano, A. R., Dada, L., and Podesta, E. J. Lipoxygenase products as common intermediates in cyclic AMP-dependent and -independent adrenal steroidogenesis in rats. J. Mol. Endocrinol., 1: 147-154, 1988.
215. Wang, X-Q., Otsuka, M., Takagi, J., Kobayashi, Y., Sato, F., and Saito, Y. Inhibition of adenylyl cyclases by 12(S)-hydroxyeicosatetraenoic acid. Biochem. Biophys. Res. Commun., 228: 81-87, 1996.
216. Hagmann, W. Cell proliferation status, cytokine action and protein tyrosine phosphorylation modulate leukotriene biosynthesis in a basophil leukaemia and a mastocytoma cell line. Biochem. J., 299: 467-472, 1994.
217. Lepley, R. A., Muskardin, D. T., and Fitzpatrick, F. A., Tyrosine kinase activity modulates catalysis and translocation of cellular 5-lipoxygenase. J. Biol. Chem., 271: 6179-6184, 1996.
218. O'Donnell, V. B., Spycher, S., and Azzi, A. Involvement of oxidants and oxidant-generating enzyme(s) in tumour-necrosis-factor-α-mediated apoptosis: role for lipoxygenase pathway but not mitochondrial respiratory chain. Biochem. J., 310: 133-141, 1995.
219. Peppelenbosch, M. P., Tertoolen, L. G. J., den Hertog, J., and de Laat, S. W. Epidermal growth factor activates calcium channels by phospholipase A2/5-lipoxygenase-mediated leukotriene C4 production. Cell, 69: 295-303, 1992.
220. Crawford, D., Zbinden, I., Amstad, P., and Cerutti, P. Oxidant stress induces the proto-oncogenes c-fos and c-myc in mouse epidermal cells. Oncogene, 3: 27-32, 1988.
221. Buttke, T. M., and Sandstrom, P. A. Oxidative stress as a mediator of apoptosis. Immunol. Today, 15: 7-10, 1994.
222. Anderson, K. M., Seed, T. M., Peng, J., Jajeh, A., Meng, J., and Harris, J. E. Morphologic changes of apoptosis induced in human chronic myelogenous leukemia "blast" cells by SC41661A (Searle), a selective inhibitor of 5-lipoxygenase. Scanning Microsc., 8: 675-686, 1994.
223. Timar, S., Silletti, S., Bazaz, R., Raz, A., and Honn, K. V. Regulation of melanoma-cell motility by the lipoxygenase metabolite 12-(S)-HETE. Int. J. Cancer, 55: 1003-1010, 1993.
224. Ford-Hutchinson, A. W., Bray, M. A., Doig, M. V., Shipley, M. E., and Smith, M. J. H. Leukotriene B, a potent chemokinetic and aggregating substance released from polyrmorphonuclear leukocytes. Nature (Lond.), 286: 264-265, 1980.
225. Strasser, T., Fischer, S., and Weber, P. C. Inhibition of leukotriene B4 formation in human neutrophils after oral nafazatrom (Bay g 6575). Biochem. Pharmacol., 34: 1891-1894, 1985.
226. Keshavarzian, A., Sedghi, S., Kanofsky, J., List, T., Robinson, C., Ibrahim, C., and Winship, D. Excessive production of reactive oxygen metabolites by inflamed colon: analysis by chemiluminescence probe. Gastroenterology, 103: 177-185, 1992.
227. Papadogiannakis, N., and Barbieri, B. Lipoxygenase inhibitors counteract protein kinase C mediated events in human T lymphocyte proliferation. Int. J. Immunopharmacol., 19: 263-275, 1997.
228. Rao, T. S., Currie, J. L., Shaffer, A. F., and Isakson, P. C. Evaluation of 5-lipoxygenase inhibitors, Zileuton, A-78773 and ICI-D-2138 in an ionophore (A-23187)-induced pleural inflammation model in the rat. Life Sci., 53: PL 147-PL152, 1993.
229. Sirois, P., Borgeat, P., Lauziere, M., Duhe, L., Rubin, P., and Kesterson, J. Effect of Zileuton (A-64077) on the 5-lipoxygenase activity of human whole blood ex vivo. Agents Actions, 34: 117-120, 1991.
230. Braeckman, R. A., Granneman, G. R., Rubin, P. R., and Kesterson, J. W. Pharmacokinetics and metabolism of the new 5-lipoxygenase inhibitor A-64077 after single oral administration in man. J. Clin. Pharmacol., 29: 837, 1989.
231. Yoshimoto, T., Yokoyama, C., Ochi, K., Yamamoto, S., Maki. Y., Ashida, Y., Terao, S., and Shiraishi, M. 2,3,5-Trimethyl-6-(12-hydroxy-5,10-dodecadiy-nyl)-1,4-benzoquinone (AA861), a selective inhibitor of the 5-lipoxygenase reaction and the biosynthesis of slow-reacting substance of anaphylaxis. Biochim. Biophys. Acta, 713: 470-473, 1982.
232. Nakadate, T., Yamamoto, S., Aizu, E., and Kato, R. Inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced increase in vascular permeability in mouse skin by lipoxygenase inhibitors. Jpn. J. Pharmacol., 38: 161-168, 1985.
233. Walker, E. R. H. The design of therapeutically effective 5-lipoxygenase inhibitors. Eur. J. Med. Chem., 30: S399-S416, 1995.
234. Yates, R. A., McMillan, R. M., Ellis, S. H., Hutchison, M., Gilmore, E., Wilkinson, D., and Williams, A. J. A new non redox 5-lipoxygenase inhibitor ICI D2138 is well tolerated and inhibits blood leukotriene synthesis in healthy volunteers. Am. Rev. Respir. Dis., 45: A745, 1992.
235. Khan, M. A., Hoffbrand, A. V., Mehta, A., Wright, F., Tahami, F., and Wickremasinghe, R. G. MK 886, an antagonist of leukotriene generation, inhibits DNA synthesis in a subset of acute myeloid leukaemia cells. Leuk. Res., 17: 759-762, 1993.
236. Brideau, C., Chan, C., Charleson, S., Denis, D., Evans, J. F., Ford-Hutchinson, A. W., Fortin, R., Gillard, J. W., Guay, J., Guevremont, D., Hutchinson, J. H., Jones, T. R., Leger, S., Mancini, J. A., McFarlane, C. S., Pickett, C., Piechuta, H., Prasit, P., Riendeau, D., Rouzer, C. A., Tagari, P., Vickers, P. J., Young, R. N., and Abraham, W. M. Pharmacology of MK-0591 (3-[1-(4-chlorobenzyl)-3-(t-butylthio)-5-(quinolin-2-yl-methoxy)-indol-2-yl]-2, 2-dimethyl propanoic acid), a potent, orally active leukotriene biosynthesis inhibitor. Can. J. Physiol. Pharmacol., 70: 799-807, 1992.
237. Diamant, Z., Timmers, M. C., van der Veen, H., Friedman, B. S., De Smet, M., Depre, M., Milliard, D., Bel, E. H., and Sterk, P. J. The effect of MK-0591, a novel 5-lipoxygenase activating protein inhibitor, on leukotriene biosynthesis and allergen-induced airway responses in asthmatic subjects in vivo. J. Allergy Clin. Immunol., 95: 42-51, 1995.
238. Muller-Peddinghaus, R., Kohlsdorfer, C., Theisen-Popp, P., Fruchtmann, R., Perzborn, E., Beckermann, B., Buhner, K., Ahr, H-J., and Mohrs, K-H. BAY X1005, a new inhibitor of leukotriene synthesis: in vivo inflammation pharmacology and pharmacokinetics. J. Pharmacol. Exp. Ther., 267: 51-57, 1993.
239. Hortsmann, R., Beckermann, B., Boettcher, M., Dietrich, H., Lemm, G., Seitz, I., and Fauler, J. Clinical pharmacological investigations with the new leukotriene synthesis inhibitor BAY X1005. Am. J. Respir. Crit. Care Med., 149: A465, 1994.
240. Yu, S. S., Djuric, S. W., Dygos, J. H., Tsai, B. S., Paulson, S. K., Smith, P. F., and Fretland, D. J. SC-53228. Drugs Future, 19: 1093-1097. 1994.
241. O'Shaughnessy, T. C., Georgiou, P., Howland, K., Dennis, M., Compton, C H., and Barnes, N. C. Effect of pranlukast, an oral leukotriene receptor antagonist, on leukotriene D4 (LTD4) challenge in normal volunteers. Thorax, 52: 519-522, 1997.
242. Grossman, J., Bronsky, E., Busse, W., Montanaro, A., Southern, L., Tinkelman, D., Dubb, J., and Faiferman, I. A multicenter, double-blind, placebo-controlled study to evaluate the safety, tolerability and clinical activity of oral, twice-daily LTA, pranlukast (SB 205312) in patients with mild to moderate asthma. J. Allergy Clin. Immunol., 95: 352, 1995.
243. Smith, L. J., Geller, S., Ebright, L., Glass, M., and Thyrum, P. T. Inhibition of leukotriene D4-induced bronchoconstriction in normal subjects by the oral LTD4 receptor antagonist ICI 204,219. Am. Rev. Respir. Dis., 141: 988-992, 1990.
244. Lin, C-C., and Shieh, D-E. The anti-inflammatory activity of Scutellaria rivularis extracts and its active components, baicalin, baicalein and wogonin. Am. J. Chin. Med., 24: 31-36, 1996.